Xilio Therapeutics, Inc.
SEC CIK 1840233 · XLO · last insider filing 2026-06-12
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Shannon James Samuel | Director | filed 2024 - 2026 |
| Bonstein Sara | Director | filed 2021 - 2026 |
| Brennan Aoife | Director | filed 2024 - 2026 |
| Ross Robert W. | Director | filed 2022 - 2026 |
| Xu Yuan | Director | filed 2022 - 2026 |
| Curran Daniel J. | Director | filed 2021 - 2026 |
| Bello Akintunde Olatokumbo | Director | filed 2025 - 2026 |
| Blanchard Cheryl R | Director | filed 2026 - 2026 |
| Russo Rene | Director · PRESIDENT AND CEO | filed 2021 - 2026 |
| Clancy Paul J | Director | filed 2021 - 2025 |
| Rossi Christina | Director | filed 2021 - 2025 |
| Heyman Tomas J. | Director | filed 2022 - 2023 |
| Ross Michael Jay | Director | filed 2021 - 2022 |
| Lynch Daniel | Director | filed 2021 - 2021 |
| Humphrey Rachel | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | filed 2023 - 2026 |
| Frankenfield Christopher James | Chief Operating Officer | filed 2023 - 2026 |
| Luptakova Katarina | Chief Medical Officer | filed 2023 - 2026 |
| Huber Martin H. Jr. | President of R&D and CMO | filed 2021 - 2023 |
| English Edward C | Principal Accounting Officer | filed 2022 - 2023 |
| Giovine Salvatore | Chief Financial Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.